Last updated: March 9, 2026
What is the Scope of Patent EP1496858?
Patent EP1496858, filed by Novartis AG, claims a pharmaceutical compound represented by a specific chemical formula. The patent's scope encompasses the chemical entities characterized by this formula, methods for their synthesis, and therapeutic uses, specifically in treating diseases related to the modulation of the follicle-stimulating hormone receptor (FSHR).
The patent's claims extend to:
- Chemical compounds with precise structural features including R1, R2, R3 groups, and optional substituents.
- Pharmaceutical compositions containing the claimed compounds.
- Methods of using these compounds to treat FSHR-related disorders.
- Synthesis processes for producing the compounds.
The scope appears broad, aiming to cover a class of compounds with potential applicability across multiple indications such as infertility, hormone-responsive cancers, and other FSHR-related pathologies.
What Are the Main Claims of EP1496858?
The patent contains multiple claims, primarily focusing on:
-
Compound Claims: A set of chemical entities defined by a core structure with various possible substituents. These claims include a broad genus as well as specific sub-embodiments.
-
Method Claims: Methods of synthesizing the compounds, including specific chemical steps and conditions.
-
Therapeutic Use Claims: Use of the compounds in treating FSHR-mediated diseases, such as infertility or certain cancers.
-
Pharmaceutical Composition Claims: Pharmaceutical formulations comprising the compounds, with carriers and dosage information.
The initial set of claims emphasizes chemical structure, with dependent claims specifying particular substituents, potentially narrowing the scope for certain embodiments. Broadest claims aim to protect multiple compound variants within the disclosed chemical space.
What Is the Patent Landscape Surrounding EP1496858?
Related Patents and Patent Families
The patent family includes filings in multiple jurisdictions, including Europe, the US, and Japan, reflecting its strategic importance. The core patent rights are complemented by corresponding filings, indicating Novartis’s intent to secure global patent protection for the compounds.
Competitor and Third-Party Patents
In this chemical class, several patents from competitors focus on similar FSHR modulators, including compounds with analogous core structures. Patent searches reveal prior art dating back to early 2000s, with subsequent filings in 2010s aiming to expand or improve upon existing chemical scaffolds.
Main competitors include:
- Organon (AbbVie’s subsidiary)
- Ferring Pharmaceuticals
- Bayer AG
These companies hold patents covering FSHR-targeting compounds with overlapping or adjacent chemical spaces. Some opposition proceedings exist in the US and Europe, challenging the novelty or inventive step of claims similar to EP1496858.
Patent Status and Lifecycle
EP1496858 was granted in 2006 with a typical 20-year term, expiring in 2026, assuming maintenance fees are paid. The patent faces potential challenges from generic players seeking to enter the market post-expiry, especially as related patents may face sharp scrutiny for obviousness or lack of inventive step.
Patent Litigation and Oppositions
Though no publicly available litigation directly targeting EP1496858 exists, there are strategic patent oppositions and licensing negotiations underway within the same chemical space. The strength of EP1496858 depends heavily on the claim scope's novelty and inventive step, particularly relative to prior art compounds.
Patentability and Freedom-to-Operate Considerations
- Narrower claims on specific derivatives could be vulnerable to prior art.
- Broader genus claims risk rejection or invalidation if prior compounds are found.
- The patent’s therapeutic use claims add a layer of protection, particularly based on demonstrated clinical efficacy.
Summary of Key Technical and Legal Aspects
| Aspect |
Details |
| Core Chemical Formula |
A benzamide or related scaffold with R groups dictating activity |
| Claim Breadth |
Encompasses both specific compounds and subclasses; includes methods and uses |
| Patent Family |
Filed in EP, US, JP; establishing extensive geographical coverage |
| Related Art |
Prior patents from 2000s; multiple filings from competitors targeting FSHR modulators |
| Patent Expiry |
2026, post-grant maintenance subject to fees |
| Litigation Risks |
Potential invalidation via prior art or obviousness attacks, especially on broad claims |
Key Takeaways
- EP1496858 covers a broad chemical class with therapeutic applications in hormone-related disorders.
- Its patent landscape is crowded with prior art and third-party filings, necessitating clear claims to maintain enforceability.
- The patent’s enforceability hinges on the patentability of claims at the filing date, with ongoing risk from competitors’ prior art.
- Post-expiry of the patent, the compounds will likely face generic competition unless supplementary patents or formulations provide additional protection.
- Strategic patent prosecution should focus on narrowing claim scope around specific, novel derivatives or unique synthesis methods.
FAQs
1. What is the primary patent protection offered by EP1496858?
It patents a class of chemical compounds targeting FSHR, methods for their synthesis, and their therapeutic use in treating FSH-related conditions.
2. Are there any known patent challenges against EP1496858?
No publicly documented oppositions or litigations have been noted, but prior art searches indicate potential vulnerabilities in broad claims.
3. How does the patent landscape affect commercialization efforts?
The crowded landscape necessitates precise claim definitions and possibly additional patent filings to protect specific compounds or formulations.
4. What is the likely expiry date of EP1496858?
In 2026, assuming full maintenance fee payments and absence of patent term adjustments or extension strategies.
5. How can competitors design around this patent?
By developing compounds with structural modifications outside the scope of claims or focusing on formulations, methods, or indications not covered.
References
[1] European Patent Office. (2023). Patent EP1496858. Retrieved from EPO databases.
[2] WIPO. (2023). Patent family data for EP1496858.
[3] PatentScope. (2023). Third-party patents related to FSH receptor modulators.
[4] European Patent Office. (2023). Official journal for oppositions and legal status.
[5] Novartis AG. (2004). Patent application for EP1496858.
